General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Corporate governance

Novartis is fully committed to good corporate governance. The Group’s principles and rules on corporate governance are laid down in the Articles of Incorporation, the Regulations of the Board and the Charters of the Board Committees.

The Board’s Governance, Nomination and Corporate Responsibilities Committee reviews these principles and rules regularly in light of prevailing best practices and forwards suggestions for improvement to the full Board for approval.

On request, Novartis will provide shareholders with a printed copy of our Annual Report or 20-F free of charge. These documents contain our complete audited financial statements. Please use the following order form to complete your request.

Articles of Incorporation

Regulations of the Board
(full version including both the regulations and all committee charters)

Compensation Committee Charter
Audit and Compliance Committee Charter
Governance, Nomination and Corporate Responsibilities Committee Charter
Risk Committee Charter
Research & Development Committee Charter
Appendix: Independence Criteria for the Board of Directors and its Committees
Hiring Restrictions for Auditors
Audit and Compliance Committee Pre-Approval Policy
Pre-approval Framework: Audit Services
Novartis Code of Ethical Conduct for CEO and Senior Financial Officers
Stock chart